CategorySymptoms and treatments

ProfG has turned into a Smurf…Dear Neuro stop him turning into Papa!

ProfG has been banging-on about “Treat early and effectively to save brain”, until he is blue in the face….So much so, that he has turned into a Smurf Sadly there are still many of his colleagues that don’t buy into this… and follow the mantra of “There….There, we’ll get ya a nice wheel chair” The vast majority of neuros and pharma bods still...

T cells bite the dust

An interesting presentation from this years MSVirtual2020 was presentation by Dr Beatrice Wasser on ‘GlcNac signalling to reduce T cell pathogenicity in MS’. Abstract Background: Both adaptive and innate immune cells infiltrate the CNS during multiple sclerosis (MS) and in its animal model experimental autoimmune encephalomyelitis (EAE). Pathogenic T cells are known as key drivers of...

Natalizumab EDI

As you all know natlaizumab is typically dosed at 4 week intervals = standard dose interval. This stops lymphocytes and probably monocytes entering the brain and so stops immune survellience of the brain, exposing people to risks of brain infection with JC virus that causes PML By extending the interval to 6 weeks (extended dosing interval = EDI). This seems to reduce the risk of PML without...

Progressive MS – Masitinib another duck lines up at MSVirtual2020

There is further hope in the horizon for progressive MS. The Phase III clinical trials were announced at MS Virtual 2020 this Sunday, adding a second third agent to the potential hopefuls in the progressive MS armamentarium. The first two being ocrelizumab and siponimod. Masitinib is designed to block the activity of multiple cell types, including microglia/macrophages, neutrophils, mast cells...

MSVirtual2020: ChariotMS

Whilst COVID-19 continues to be rather all-consuming, we’ve been extremely fortunate signing all relevant contracts at the start of the pandemic enabling us to keep the momentum of ChariotMS. Recruitment was meant to start this month, however COVID-19 threw us a final dummy, and we are now on course to enrol the first participant in Jan 2021. I can hardly describe how excited I am this...

#MSCOVID19 Whilst two swallows may make a summer…but it seems two COVID-19 papers make a bummer….for anti-CD20 therapy

Banksy and the Swallow bummer = a disappointing or unpleasant situation or experience. When it all started the Great and the Good (Neuro) experts looked at the different DMT and thought about the risks Disease-Modifying Therapies During the COVID-19 Outbreak: A Narrative Review of International and National Recommendations Smathorn et al.  International Journal of MS Care (2020) 22...

Fingolimod Trial from Years ago surfaces and guess what, the approved dose works…….Amazing

What is the optimum dose for fingolimod? In the early studies I think they used 5mg and 1.25mg and they both worked about the same. So Novartis dropped the dose and guess what? It worked. They dropped it again and guess what?, it still worked , well at least as good glatiramer acetate but not as good as the approved 0.5mg dose according to this trial started in 2012. Why go to all this trouble...

Reducing issues with CD20 depletion

What is the optimum dose and dosing schedule for ocrelizumab? We don’t know because the manufacturers haven’t done the studies, but rituximab it seems that we can reduce the dose. A common dose was 1000mg and it was reduced to 500mg. Efficacy was maintained and impotant it reduced the loss of circulating antibodies. This is important as the loss of such antibodies was associated with...

Rocky Mountain Ritixumab Fever

This is the real life experience of a single centre in the USA. As you can see their experience with CD20 depletion was essentailly as good or better to other commercial products, Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E.Ann Clin Transl Neurol. 2020 Aug 6. doi: 10.1002/acn3.51111...

Best Neuroprotection is to stop inflammation from occurring.

We hear about the “real MS” as so terms as if it is un-treatable….but if we want to stop nerve damage, we have to deal with the inflammarory reaction as quickly and as effectively as possible. Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years.Pulido-Valdeolivas I, Andorrà M, Gómez-Andrés D...

Translate

Categories

Recent Posts

Recent Comments

Archives